Charles River Laboratories International (CRL)
NYSE Market Closed
Charles River Laboratories International, Inc. is a contract research and manufacturing support company serving the pharmaceutical, biotechnology, medical device, academic, and government research markets. Founded in 1947, the company plays a central role in the outsourced life sciences ecosystem by helping clients move potential therapies from early research through preclinical development and quality testing.
The business is best known for its research models and related services. Charles River supplies laboratory animal models with defined genetic and health characteristics, along with specialized services that support preclinical studies. These models are used by researchers to study disease biology, evaluate drug candidates, and generate data before human clinical trials begin.
Beyond research models, Charles River offers discovery and safety assessment services. This part of the company supports drug developers with activities such as target validation, pharmacology, toxicology, and other studies required to assess whether a compound is suitable for further development. By providing these services externally, the company allows customers to access scientific expertise and infrastructure without building all capabilities in-house.
Charles River also operates a manufacturing support segment that includes microbial testing products, biologics testing services, and avian vaccine services. These offerings help customers confirm product safety, quality, and regulatory compliance, particularly in biologics and advanced therapies.
The company’s position is distinctive because it spans multiple stages of the research and development process. Its customers rely on it not only for laboratory models, but also for scientific services and quality-control tools that are embedded in drug discovery, preclinical testing, and biomanufacturing workflows.
Last updated
- Market Cap
- 8.95B
- P/E
- —
- P/FCF
- 30.17
- P/S
- 2.22
- Enterprise Value
- 11.42B
- Sector
- Industrials
- Industry
- Commercial Physical and Biological Research
- Address
- 251 BALLARDVALE ST, WILMINGTON, MA, 01887
Cell Banking Outsourcing Market: 16%+ CAGR (2026-2031), Expanding with Rising Demand for Biologics and Regenerative Medicine Services, Says Mordor Intelligence
Global Plasmid DNA Manufacturing Market Anticipates Impressive Growth Trajectory at a CAGR of ~18% by 2034 | DelveInsight
Global AAV Vector Manufacturing Market Gearing Up for Outstanding Expansion at a CAGR of ~22% by 2034 | DelveInsight
Drug Development Services Market Research Report 2026: $50+ Bn Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F
Practical Implementation of GCP in Veterinary Course: Approaches to the Design, Set-up and Conduct in Compliance with VICH Good Clinical Practice (GCP) Principles (ONLINE EVENT: May 13th-14th, 2026)
[Latest] Global Adeno Associated Virus Vector Manufacturing Market Size/Share Worth USD 9.87 Billion by 2035 at a 13.4% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Growth Rate, Value, SWOT Analysis)
Lead Optimization Services in Drug Discovery Market to Reach USD 10.26 Billion by 2034, Driven by Rising R&D Activity
Cell & Gene Therapy Quality Control Market Poised USD 22.81 Billion at 25.74% CAGR by 2034
Biologics Safety Testing Market to Rise at 13.64% CAGR, Soars USD 14.45 Bn by 2034
Pharmaceutical Contract Research Services Market Report 2025-2035: M&A, Partnerships, and Biologics Focus
Global Bioanalytical Testing Services Market to Observe Stunning Growth at a CAGR of ~16% by 2032 | DelveInsight
Residual DNA Testing Global Market Forecast to 2030 | Novel Modalities, Emerging Markets Growth, Continuous Processing Integration, and Rising CRO/CDMO Outsourcing
Pharma Contract Research Organization (CRO) Services Market to Cross USD 36.66 Billion in 2025, Expanding at a CAGR of 10.04%
The 2 Worst Performing S&P 500 Stocks YTD: Buy, Sell, or Avoid?
Molecular Breeding Market Insights, Competitive Intelligence and Growth Forecast 2025-2030 - CRISPR and Genomic Advances are Driving Crop Innovation
Global Cell and Gene Therapy Manufacturing Market to Reach ~USD 10 Billion by 2032 | DelveInsight
Pharmaceutical Regulatory Affairs Research Report 2025-2030: Entry of Companies into the Global Market Fueling Growth
Clinical Trials Support Services Market Poised for Notable Expansion by 2030, Driven by Substantial Investments in R&D from Pharmaceutical and Biopharmaceutical Companies
Biologics Contract Manufacturing Market Industry Report 2024-2035: Mammalian Expression System is Set to Capture the Highest Share of the Market During the Forecast Period
Healthcare Analytical Testing Services Market to Surpass Valuation of USD 15.55 Billion by 2031 | SkyQuest Technology
- Market Cap
Market cap is the total value of a company's shares, calculated by multiplying the stock price by the number of shares outstanding.
- 8.95B
- Enterprise Value
Enterprise value is the total value of a company, including its market cap, debt, and cash.
- 11.42B
- P/E
P/E ratio compares a company's share price to its earnings per share.
- —
- P/B
P/B ratio compares a company's share price to its book value per share.
- 3.04
- P/S
P/S ratio compares a company's share price to its revenue per share.
- 2.22
- EV / EBITDA
EV/EBITDA measures a company's value compared to its earnings before interest, taxes, depreciation, and amortization.
- 14.34
- EV / Sales
EV/Sales measures a company's value compared to its total revenue.
- 2.84
- EPS
- -3.83
- Dividend Yield
Dividend yield shows how much a company pays in dividends each year compared to its share price.
- 0%
- P/FCF
Price-to-free-cash-flow ratio compares a company's share price to the cash it generates after expenses and investments.
- 30.17
- P/CF
P/CF ratio compares a company's share price to the cash flow it generates from its operations.
- 14.74
- Free Cash Flow
Free cash flow is the cash a company has left after covering operating costs and capital expenses.
- 296.67M
- ROE
ROE measures how effectively a company uses shareholders' equity to generate profit.
- -6.28%
- ROA
ROA measures how effectively a company uses its assets to generate profit.
- -2.39%
- Debt / Equity
Debt-to-equity ratio compares a company's total debt to its shareholders' equity.
- 0.91
- Current Ratio
Current ratio measures a company's ability to pay short-term debts using its short-term assets.
- 1.36
- Quick Ratio
Quick ratio measures a company's ability to pay short-term debts using cash and other easily available assets.
- 1.03
- Cash
Cash ratio measures a company's ability to cover short-term debts using only cash and cash equivalents.
- 0.18
- Avg Volume
Average volume shows the average number of shares traded over the last 30 trading days, helping indicate liquidity.
- 924.28K
- Fundamentals Snapshot Price
Fundamentals snapshot price is the stock price used when calculating the company's financial ratios and metrics.
- 185.79
Income Statement
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Revenue | 995.83M | 994.23M | 1B | 1.03B | 984.17M |
| Gross profit | 294.66M | 309.68M | 338.79M | 357.07M | 317.73M |
| Operating income | 119.9M | -283.44M | 133.8M | 100.13M | 74.67M |
| EBITDA | 187.05M | 170.81M | 218.96M | 219.64M | 195.03M |
| Net income | -14.84M | -276.56M | 54.42M | 52.33M | 25.47M |
| Basic EPS | -0.3 | -5.57 | 1.11 | 1.06 | 0.5 |
| Diluted EPS | -0.3 | -5.56 | 1.1 | 1.06 | 0.5 |
Balance Sheet
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Total assets | 7.73B | 7.14B | 7.51B | 7.56B | 7.58B |
| Total liabilities | 4.74B | 3.92B | 4.06B | 4.16B | 4.34B |
| Total equity | 2.95B | 3.17B | 3.41B | 3.36B | 3.2B |
| Cash & equivalents | 191.83M | 213.77M | 207.1M | 182.82M | 229.36M |
| Current assets | 1.49B | 1.45B | 1.53B | 1.47B | 1.51B |
| Current liabilities | 1.09B | 1.12B | 1.12B | 1.08B | 1.05B |
Cash Flow
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Operating cash flow | 41.08M | 147.52M | 213.83M | 204.6M | 171.7M |
| Investing cash flow | -407.85M | -92.81M | -33.7M | -37.34M | -45.48M |
| Financing cash flow | 347.72M | -51.86M | -152.62M | -226.92M | -105.33M |
| Change in cash | -17.8M | 6.78M | 24.48M | -46.99M | 26.16M |
| Kind | Filing | Date | Link |
|---|---|---|---|
| edgar index | 4 — CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | View Filing | |
| edgar index | 4 — CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | View Filing | |
| edgar index | 4 — CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | View Filing | |
| edgar index | 4 — CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | View Filing | |
| edgar index | 4 — CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | View Filing | |
| edgar index | 4 — CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | View Filing | |
| edgar index | 4 — CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | View Filing | |
| edgar index | 4 — CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | View Filing | |
| edgar index | 4 — CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | View Filing | |
| form 4 | Form 4 — Barg Steven | View Filing | |
| form 4 | Form 4 — Parisotto Shannon M | View Filing | |
| form 4 | Form 4 — Creamer Victoria L | View Filing | |
| form 4 | Form 4 — Girshick Birgit | View Filing | |
| form 4 | Form 4 — Knell Michael Gunnar | View Filing | |
| form 4 | Form 4 — LaPlume Joseph W | View Filing | |
| form 4 | Form 4 — Mintz Mark | View Filing | |
| form 4 | Form 4 — Parisotto Shannon M | View Filing | |
| form 4 | Form 4 — Creamer Victoria L | View Filing | |
| form 4 | Form 4 — FOSTER JAMES C | View Filing | |
| form 4 | Form 4 — FOSTER JAMES C | View Filing | |
| form 4 | Form 4 — FOSTER JAMES C | View Filing | |
| form 4 | Form 4 — FOSTER JAMES C | View Filing | |
| form 4 | Form 4 — FOSTER JAMES C | View Filing | |
| form 4 | Form 4 — FOSTER JAMES C | View Filing | |
| form 4 | Form 4 — FOSTER JAMES C | View Filing | |
| form 4 | Form 4 — Girshick Birgit | View Filing | |
| form 4 | Form 4 — Knell Michael Gunnar | View Filing | |
| form 4 | Form 4 — LaPlume Joseph W | View Filing | |
| form 4 | Form 4 — Mintz Mark | View Filing | |
| form 4 | Form 4 — Parisotto Shannon M | View Filing | |
| form 4 | Form 4 — Parisotto Shannon M | View Filing | |
| form 4 | Form 4 — Parisotto Shannon M | View Filing | |
| form 4 | Form 4 — Creamer Victoria L | View Filing | |
| form 4 | Form 4 — Girshick Birgit | View Filing | |
| form 4 | Form 4 — Girshick Birgit | View Filing | |
| form 4 | Form 4 — Knell Michael Gunnar | View Filing | |
| form 4 | Form 4 — LaPlume Joseph W | View Filing | |
| form 4 | Form 4 — Mintz Mark | View Filing | |
| form 4 | Form 4 — Coleman Glenn | View Filing | |
| edgar index | 4 — CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | View Filing | |
| edgar index | 4 — CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | View Filing | |
| edgar index | 4 — CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | View Filing | |
| edgar index | 4 — CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | View Filing | |
| edgar index | 4 — CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | View Filing | |
| edgar index | 4 — CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | View Filing | |
| form 4 | Form 4 — LaPlume Joseph W | View Filing | |
| form 4 | Form 4 — Knell Michael Gunnar | View Filing | |
| form 4 | Form 4 — Girshick Birgit | View Filing | |
| form 4 | Form 4 — Mintz Mark | View Filing | |
| form 4 | Form 4 — Parisotto Shannon M | View Filing | |
| form 4 | Form 4 — Creamer Victoria L | View Filing | |
| form 4 | Form 4 — LaPlume Joseph W | View Filing | |
| form 4 | Form 4 — Knell Michael Gunnar | View Filing | |
| form 4 | Form 4 — Girshick Birgit | View Filing | |
| form 4 | Form 4 — Girshick Birgit | View Filing | |
| form 4 | Form 4 — Mintz Mark | View Filing | |
| form 4 | Form 4 — Parisotto Shannon M | View Filing | |
| form 4 | Form 4 — Creamer Victoria L | View Filing | |
| edgar index | 4 — CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | View Filing | |
| edgar index | 4 — CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | View Filing | |
| edgar index | 4 — CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | View Filing | |
| edgar index | 4 — CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | View Filing | |
| form 4 | Form 4 — Andrews Nancy C | View Filing | |
| form 4 | Form 4 — Andrews Nancy C | View Filing | |
| edgar index | SD — CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | View Filing | |
| edgar index | 8-K — CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | View Filing | |
| edgar index | 4 — CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | View Filing | |
| edgar index | 4 — CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | View Filing | |
| edgar index | 4 — CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | View Filing | |
| edgar index | 4 — CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | View Filing | |
| edgar index | 4 — CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | View Filing | |
| edgar index | 4 — CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | View Filing | |
| edgar index | 4 — CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | View Filing | |
| edgar index | 4 — CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | View Filing | |
| eight k text | 8-K — 8-K | View Filing |